A related commentary discusses this research. The TRIUMPH investigators have demonstrated the effects of a promising intervention in a triple half-dose combination therapy, which logically extends findings from prior research to improve BP control among patients with mild to moderate hypertension. This study contributes to the existing literature demonstrating the essential role of fixed-dose combination therapy as a viable strategy for BP control on a global scale. There are however some limitations to the study: First, the use of usual care as a comparator increases the risk of performance bias because study participants and personnel were not blinded, and the results may overestimate the effect of the intervention Second, the primary outcome of BP control was assessed only through 6 months, whereas patients with hypertension will usually be advised to continue BP-lowering pharmacotherapy for longer periods. Third, the study was performed in a single country and evaluation of the efficacy and safety of the intervention is needed in more diverse populations before it can be broadly adopted.